Contingencies and Certain Commitments (Product Litigation, Commercial and Other Matters, Legal Proceedings) (Details) $ in Millions		1 Months Ended			3 Months Ended		9 Months Ended		12 Months Ended
		Sep. 30, 2021 lagoon	Jul. 31, 2021 USD ($)	Feb. 29, 2020 classAction	Oct. 03, 2021 USD ($)	Sep. 27, 2020 USD ($)	Oct. 03, 2021 USD ($)	Sep. 27, 2020 USD ($)	Dec. 31, 2018 manufacturer lagoon	Dec. 31, 2017 classAction	Dec. 31, 2013 lagoon
Loss Contingencies [Line Items]
Loss on litigation settlement | $	[1]				$ 38	$ (17)	$ 458	$ 5
EpiPen [Member]
Loss Contingencies [Line Items]
Loss on litigation settlement | $			$ 345				$ 345
Pfizer And Hospira And Various Other Manufacturers Versus Mississippi Attorney General [Member] | Docetaxel [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of defendants other than main defendant | manufacturer									8
Array Securities Litigation [Member]
Loss Contingencies [Line Items]
Number of class actions filed | classAction										2
Zantac Litigation [Member]
Loss Contingencies [Line Items]
Number of class actions filed | classAction				2
Environmental Remediation Litigation [Member]
Loss Contingencies [Line Items]
Feasibility study, number of lagoons | lagoon		2							2		2

[1] The first nine months of 2021 primarily includes an amount to resolve a Multi-District Litigation relating to EpiPen pending against the Company in the U.S. District Court for the District of Kansas for $345 million, which remains subject to court approval. See Note 12A5.